# Abzena ThioBridge® deal highlights undervaluation

- Link: https://www.directorstalkinterviews.com/abzena-thiobridge-deal-highlights-undervaluation/412722992
- Published: 2017-02-02T10:59:29+00:00
- Author: Giles Arbor

**[⌊Hardman & Co Report⌉⌊Hardman & Co Report⌉[Abzena Plc** (LON:ABZA) is an integrated
group offering a broad range of services and technologies to improve the chances
of discovering and developing effective biopharmaceutical drugs. With strong footprints
in both the US and UK, the company provides a fee-for-service offering with the 
additional opportunity to embed its technology – ‘Abzena Inside’ – into commercial
products, on which it will derive a long-term royalty stream. Abzena has signed 
a licensing deal with a US biopharmaceutical company for the use of its ThioBridge
technology. This deal has a potential value exceeding $300m and has significantly
boosted market confidence in the company.

 
 Strategy: Abzena has a dual strategic objective of providing enabling technology
on a fee-for-service basis and, where possible, to secure technology agreements 
from embedding its patented technology and ‘know-how’ into customers’ final products
to generate future licence revenues and, potentially, royalties.

ThioBridge: Antibody Drug Conjugates (ADCs) link the tumour targeting properties
of antibodies with a cytotoxic payload, but do have some drawbacks. Abzena has developed
ThioBridge technology to produce more homogenous and stable ADCs thereby overcoming
many of the inherent issues.

Licensing agreement: Abzena has announced a new licensing deal with a San Diego-
based biopharmaceutical company for the development of up to 10 ADCs targeted at
various cancers. The deal is potentially worth up to $300m in access fees, and development
and regulatory milestones. It also comprises a Service Agreement with Abzena’s Chemistry
division.

Risks: There are inherent clinical trial and commercialisation risks in drug development.
Any product emerging under the agreement would become part of the ‘Abzena Inside’
portfolio. However, in all probability, not all 10 of the potential ADCs under the
agreement will reach commercialisation.

Investment summary: The market reacted very positively to this news which was long
overdue. The agreement represented further validation of Abzena Plc technology, 
increased market confidence that more deals will be done, and highlighted the undervaluation
of the stock, with the fast-growing service business alone more than justifying 
the current market capitalisation.

Share on:
